News

Zacks Investment Research on MSN2d
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...
PMLive2d
Gilead Sciences and Kymera enter oncology partnership worth up to $750m
Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Medical Dialogues2d
Gilead Sciences, Kymera Therapeutics ink pact to develop novel oral molecular glue CDK2 degraders
Gilead Sciences, Inc. and Kymera Therapeutics, Inc., have entered into an exclusive option and license agreement for ...
Seeking Alpha3d
KYMR Kymera Therapeutics, Inc. - Seeking Alpha
A high-level overview of Kymera Therapeutics, Inc. (KYMR) stock. View (KYMR) real-time stock price, chart, news, analysis, analyst reviews and more.
Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485
Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.